Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

7.520 +0.070 (+0.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,275,266
Open 7.410
Bid (Size) 7.500 (7)
Ask (Size) 7.730 (1)
Prev. Close 7.450
Today's Range 7.410 - 7.700
52wk Range 6.280 - 33.97
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
-66.55%
-66.55%
1 Month
+0.13%
+0.13%
3 Month
-25.17%
-25.17%
6 Month
-39.26%
-39.26%
1 Year
-67.29%
-67.29%

More News

Read More
NASDAQ: AUPH Long Term Investor Alert: Investigation of Potential Wrongdoing at Aurinia Pharmaceuticals Inc.
Via SBWire
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Why Aurinia Pharmaceuticals Stock Is Plunging
Via Benzinga
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Via Benzinga
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread
Via Investor's Business Daily
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
Via Benzinga
Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Aurinia Pharmaceuticals Inc. (AUPH) Investors of Class Action and Last Day to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
AURINIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
AUPH FINAL DEADLINE TUESDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 14 Deadline in Securities Class Action - AUPH
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
NASDAQ:AUPH Investor Notice: Deadline on June 14, 2022 in Lawsuit Against Aurinia Pharmaceuticals Inc.
Via SBWire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
From Aurinia Pharmaceuticals Inc.
Via Business Wire
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Via Benzinga
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPH
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.